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1 Alleles polymorphism of microsomal epoxide hydrolase gene
(mEPHX) as modiﬁer factor in cystic ﬁbrosis
N. Rohovyk1,2, N. Vishtak3, H. Makuh3, L. Bober4, O. Lyha2. 1Danylo Halytsky
Lviv National Medical University, Lviv, Ukraine; 2Western Ukrainian Specialized
Children’s Medical Centre and Cystic Fibrosis Regional Centre, Lviv, Ukraine;
3Institute of Hereditary Pathology of National Academy of Medical Sciences of
Ukraine, Lviv, Ukraine; 4Western Ukrainian Specialized Children’s Medical Centre
and Cystic Fibrosis regional centre, Lviv, Ukraine
Introduction:mEPHX enzyme activity and stability are strong factors for resistance
to development of chronic obstructive pulmonary disease. The mEPHX allelic
polymorphism T337C and A415G could be considered as a modifying the severity
of chronic pulmonary disease in CF patients.
Aim: To establish mEPHX T337C and A415G alleles and genotypes distribution
among CF patients F508del homozygotes.
Methods: The ampliﬁcation of DNA sequences using PCR was carried on. Am-
pliﬁed products were subjected to digestion and electrophoresed on 2% agarose
gel.
Results: We analyzed 35 CF patients homozygotes for F508del and 157 no-CF
persons as control. In patients with mild form of CF 415AA genotype is more
common (75.0%) than among patients with severe form (52.6%). mEPHX 415GG
genotype was recorded in half rarely in patients with CF mild form than in patients
with severe form (26.3%). The frequency of 415GG genotype was higher among
patients with CF (OR= 2.77, p< 0.05) as compared to control group.
Conclusions: The association between mEPHX alleles and the severity of the
disease among CF patients was not conﬁrmed. To clarify the higher frequency
of mEPHX 415GG genotype among CF patient the mEPHX enzyme activity shall
to be studied.
2 Genome sequence of the Danish epidemic strain of Achromobacter
ruhlandii
K.J. Handberg1, T. Andreasen1, M. Wang1, W. Ridderberg1, N. Nørskov-
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Objectives: Achromobacter xylosoxidans and other Achromobacter species can
chronically colonise the airways of cystic ﬁbrosis (CF) patients. These bacteria are
increasingly reported from CF centres and have propensity to develop resistance
to all antimicrobial agents. The Danish epidemic strain (DES) is a transmissible
strain of A. ruhlandii that has spread between patients from both Danish CF centres
causing 17 of 68 (25%) primary infections with Achromobacter from 2000 to 2011.
The DES is, or has become, an exceptionally resistant clone, and infection with DES
is suspected if a patient presents with a ﬁrst-time isolate of Achromobacter showing
pan-resistance. As no genome sequence is publicly available for A. ruhlandii we
sequenced a representative of DES.
Methods: Next-Generation-Sequencing.
Results: The investigated strain was a ﬁrst-time isolate cultured in 2002 from a
patient at the CF centre at Aarhus University Hospital. By de novo assembly and
RAST analysis the genome size was estimated to 6.35Mbp with a GC-content of
67.6%. The closest neighbour in the RAST database was Achromobacter piechaudii.
The number of protein encoding genes was estimated to 5,895. The GC-content of
DES A. ruhlandii was similar to that of A. xylosoxidans strain NH44784–1996, but
the genome size and number of genes were slightly lower for A. ruhlandii. The
genome contained several potential antimicrobial resistance genes.
Conclusion: The data will serve as a framework for a comparison of all strains
involved in the DES outbreak to elucidate the molecular epidemiology and the
spread of the strain, as well as the putative acquisition of antimicrobial resistance
genes.
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of CFTR mutations and low incidence of CF disease in Galicia
(NW Spain)
C. Colon1, F. Barros2. 1C.H. Univ. de Santiago, Pediatrics, Santiago, Spain;
2Fundacio´n Pu´blica Galega de Medicina Xeno´mica, Santiago de Compostela,
Spain
Introduction: Newborn Screening for CF started in Galicia in 2003. To date
we have screened 236,784 newborns using an IRT+DNA protocol. The protocol
includes a MALDI-TOF genotyping assay for 277 mutations, 50 CFTR SNPs and
7 sex markers.
Results: We found a total of 39 newborns with 2 mutations associated to different
CF types: 14 classical CF and 25 mild, uncertain or CFTR-related disease. In
addition 192 carriers were found. 34 different mutations were detected, being
F508del the most common CF causing mutation (78.6% in classical CF and 21.9%
the group of mild, uncertain of CFTR-related disease).
If only mutations related to classical CF disease were considered, the incidence
of the disease in our population would be the lowest in caucasians: 1 in 16900
newborns affected. Including all the mutation the incidence increases to 1 in 7000
newborns. No false negative result was detected in Galicia since the initiation of
Newborn Screening CF in 2003.
Conclusion: The wide genetic variability present in the CFTR gene can be a
handicap to establish a CF newborn screening, notably in populations with a low
incidence of CF. The use of high throughput genotyping methods covering the most
prevalent mutations in the target population is a guarantee for the screening success.
4 Prevalence of DF508 mutation in patients with cystic ﬁbrosis in a
miscegenated population of the Brazilian Northeast
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Cystic Fibrosis (CF) is an inherited autosomal recessive disease. There are more
than 1,900 mutations associated with this disease and the DF508 mutation is the
most common in Caucasians. In Brazil, the frequency of the DF508 mutation varies
according to geographic and ethnic origin of patients. The population of the state
of Bahia, in Northeastern Brazil, is highly admixed and a previous study has shown
that the frequency DF508 mutation was 11.8% in cystic ﬁbrosis patients.
Objective: To determine the prevalence of DF508 mutation in CF patients followed
up at the Professor Edgard Santos School Hospital Complex, Salvador, Bahia,
Brazil.
Methodology: It was conducted a cross sectional study. The population studied
was composed of CF patients, from 0 to 20 years. After inclusion in the study, a
questionnaire was applied to collect clinical data and laboratory results and patients
underwent blood sampling to investigate DF508 mutation.
Results: Forty-four patients were included, with a mean age of 9.4±5.7 years,
median of 8.5 years, and 22 (50%) were male. The DF508 mutation was found in
14 patients (31.8%). Of those, six (42.9%) were homozygotes and eight (57.1%)
were heterozygotes. Regarding the alleles, there were 20 carriers (20/88 or 22.7%)
and 68 non-carriers (68/88 or 77.3%).
Conclusions: The frequency of the DF508 mutation is lower than that found in
populations from Brazilian Southeast, but higher than a previous study in Salvador.
The CF diagnosis was delayed and patients with the DF508 mutation had symptoms
with early onset and presented pancreatic insufﬁciency.
